Host genetics and viral infections: immunology taught by viruses, virology taught by the immune system

Current Opinion in Immunology

Volumn 18, Issue 4, 2006, Pages 413-421

  Nolan, David ^a   Gaudieri, Silvana ^a   Mallal, Simon ^a  

^a MURDOCH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ALLELE; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; DISEASE COURSE; DNA POLYMORPHISM; GENE DUPLICATION; GENE INTERACTION; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; GENETIC CONSERVATION; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HEREDITY; HLA SYSTEM; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNE SYSTEM; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; REVIEW; VIROLOGY; VIRUS CELL INTERACTION; VIRUS GENOME; VIRUS INFECTION;

HIV INFECTIONS; HIV-1; HUMANS; VIRUS DISEASES; VIRUSES;

EID: 33745408207     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coi.2006.05.015     Document Type: Review

References (59)

1. Zinsser H. Rats, Lice and History (1934), Little, Brown and Company
2. Hewitt E.W. The MHC class I antigen presentation pathway: strategies for viral immune evasion. Immunology 110 (2003) 163-169
3. Lilley B.N., and Ploegh H.L. Viral modulation of antigen presentation: manipulation of cellular targets in the ER and beyond. Immunol Rev 207 (2005) 126-144. This is an up-to-date review on viral 'immunoevasins' and their role in subverting cytotoxic T lymphocyte responses, which has particular focus on herpesviruses.
4. Orange J.S., Fassett M.S., Koopman L.A., Boyson J.E., and Strominger J.L. Viral evasion of natural killer cells. Nat Immunol 3 (2002) 1006-1012
5. Lodoen M.B., and Lanier L.L. Viral modulation of NK cell immunity. Nat Rev Microbiol 3 (2005) 59-69. This study examines the relationship between NK cells and viruses, again with a focus on herpersviruses.
6. Galvani A.P., and Slatkin M. Evaluating plague and smallpox as historical selective pressures for the CCR5-delta 32 HIV-resistance allele. Proc Natl Acad Sci USA 100 (2003) 15276-15279
7. Hummel S., Schmidt D., Kremeyer B., Herrmann B., and Oppermann M. Detection of the CCR5-delta32 HIV resistance gene in bronze age skeletons. Genes Immun 6 (2005) 371-374. This is a marvellous piece of detective work by this Historic Anthropology research group from Gottingen, Germany. This analysis of skeletal remains from >2000 years ago, along with related work involving 14th century victims of the bubonic plague [59], has clarified the role of the CCR5Δ32 mutation in historical Europe.
8. Wooding S., Stone A.C., Dunn D.M., Mummidi S., Jorde L.B., Weiss R.K., Ahuja S., and Bamshad M.J. Contrasting effects of natural selection on human and chimpanzee CC chemokine receptor 5. Am J Hum Genet 76 (2005) 291-301. This is an interesting article that outlines the purifing selection of chimpanzee CCR5 variants through evolution, which strongly corroborates similar findings in the MHC class I region [9] and implicates the involvement of SIV in both selection events.
9. de Groot N.G., Otting N., Doxiadis G.G., Balla-Jhagjhoorsingh S.S., Heeney J.L., van Rood J.J., Gagneux P., and Bontrop R.E. Evidence for an ancient selective sweep in the MHC class I gene repertoire of chimpanzees. Proc Natl Acad Sci USA 99 (2002) 11748-11753
10. Klein J., Gutknecht J., and Fischer N. The major histocompatibility complex and human evolution. Trends Genet 6 (1990) 7-11
11. Meyer D., and Thomson G. How selection shapes variation of the human major histocompatibility complex: a review. Ann Hum Genet 65 (2001) 1-26
12. Kulski J.K., Gaudieri S., Bellgard M., Balmer L., Giles K., Inoko H., and Dawkins R.L. The evolution of MHC diversity by segmental duplication and transposition of retroelements. J Mol Evol 45 (1997) 599-609
13. Bihl F., Frahm N., Di Giammarino L., Sidney J., John M., Yusim K., Woodberry T., Sango K., Hewitt H.S., Henry L., et al. Impact of HLA-B alleles, epitope binding affinity, functional avidity, and viral coinfection on the immunodominance of virus-specific CTL responses. J Immunol 176 (2006) 4094-4101. This important recent study examines several potential determinants of the CTL response to HIV infection. This highlights the role of HLA-B alleles in shaping immunodominant responses within and between individuals.
14. Kiepiela P., Leslie A.J., Honeyborne I., Ramduth D., Thobakgale C., Chetty S., Rathnavalu P., Moore C., Pfafferott K., Hilton L., et al. Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. Nature 432 (2004) 769-775
15. + T-cells. Blood 2006. in press. This study provides evidence for a correlation between highly functional HLA-specific immune responses (i.e. extending beyond interferon-γ production) and long-term non-progressor status in HIV-infected patients.
16. Stewart C.A., Horton R., Allcock R.J., Ashurst J.L., Atrazhev A.M., Coggill P., Dunham I., Forbes S., Halls K., Howson J.M., et al. Complete MHC haplotype sequencing for common disease gene mapping. Genome Res 14 (2004) 1176-1187
17. Allcock R.J., Windsor L., Gut I.G., Kucharzak R., Sobre L., Lechner D., Garrier J.G., Baltic S., Christiansen F.T., and Price P. High-density SNP mapping defines 17 distinct haplotypes of the TNF block in the Caucasian population: implications for haplotype tagging. Hum Mutat 24 (2004) 517-525
18. Tang J., and Kaslow R. The impact of host genetics on HIV infection and disease progression in the era of highly active antiretroviral therapy. AIDS 17 (2003) S51-S60
19. O'Brien S.J., Gao X., and Carrington M. HLA and AIDS: a cautionary tale. Trends Mol Med 7 (2001) 379-381
20. Scherer A., Frater J., Oxenius A., Agudelo J., Price D.A., Gunthard H.F., Barnardo M., Perrin L., Hirschel B., Phillips R.E., et al. Quantifiable cytotoxic T lymphocyte response and HLA-related risk of progression to AIDS. Proc Natl Acad Sci USA 101 (2004) 12266-12270
21. Leslie A.J., Pfafferott K.J., Chetty P., Draenert R., Addo M.M., Feeney M., Tang Y., Holmes E.C., Allen T., Prado J.G., et al. HIV evolution: CTL escape mutation and reversion after transmission. Nat Med 10 (2004) 282-289
22. Altfeld M., Addo M.M., Rosenberg E.S., Hecht F.M., Lee P.K., Vogel M., Yu X.G., Draenert R., Johnston M.N., Strick D., et al. Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1 infection. AIDS 17 (2003) 2581-2591
23. Tang J., Wilson C.M., Meleth S., Myracle A., Lobashevsky E., Mulligan M.J., Douglas S.D., Korber B., Vermund S.H., Kaslow R.A., et al. Host genetic profiles predict virological and immunological control of HIV-1 infection in adolescents. AIDS 16 (2002) 2275-2284
24. Kaslow R.A., Carrington M., Apple R., Park L., Munoz A., Saah A.J., Goedert J.J., Winkler C., O'Brien S.J., Rinaldo C., et al. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat Med 2 (1996) 405-411
25. Ioannidis J.P., Goedert J.J., McQueen P.G., Enger C., and Kaslow R.A. Comparison of viral load and human leukocyte antigen statistical and neural network predictive models for the rate of HIV-1 disease progression across two cohorts of homosexual men. J Acquir Immune Defic Syndr Hum Retrovirol 20 (1999) 129-136
26. Magierowska M., Theodorou I., Debre P., Sanson F., Autran B., Riviere Y., Charron D., and Costagliola D. Combined genotypes of CCR5, CCR2, SDF1, and HLA genes can predict the long-term nonprogressor status in human immunodeficiency virus-1-infected individuals. Blood 93 (1999) 936-941
27. Moore C.B., John M., James I.R., Christiansen F.T., Witt C.S., and Mallal S.A. Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Science 296 (2002) 1439-1443
28. Kaslow R.A., Duquesnoy R., VanRaden M., Kingsley L., Marrari M., Friedman H., Su S., Saah A.J., Detels R., Phair J., et al. A1, Cw7, B8, DR3 HLA antigen combination associated with rapid decline of T-helper lymphocytes in HIV-1 infection. A report from the multicenter AIDS cohort study. Lancet 335 (1990) 927-930
29. Mallal S., Cameron P.U., French M.A., and Dawkins R.L. MHC genes and HIV infection. Lancet 335 (1990) 1591-1592
30. Price P., Witt C., Allcock R., Sayer D., Garlepp M., Kok C.C., French M., Mallal S., and Christiansen F. The genetic basis for the association of the 8.1 ancestral haplotype (A1, B8, DR3) with multiple immunopathological diseases. Immunol Rev 167 (1999) 257-274
31. Candore G., Romano G.C., D'Anna C., Di Lorenzo G., Gervasi F., Lio D., Modica M.A., Postesio M., and Caruso C. Biological basis of the HLA-B8, DR3-associated progression of acquired immune deficiency syndrome. Pathobiology 66 (1998) 33-37
32. + T cell loss.
33. Contu L., Cerimele D., Pintus A., Cottoni F., and La Nasa G. HLA and Kaposi's sarcoma in Sardinia. Tissue Antigens 23 (1984) 240-245
34. Pollack M.S., Safai B., Myskowski P.L., Gold J.W., Pandey J., and Dupont B. Frequencies of HLA and Gm immunogenetic markers in Kaposi's sarcoma. Tissue Antigens 21 (1983) 1-8
35. Mann D.L., Murray C., O'Donnell M., Blattner W.A., and Goedert J.J. HLA antigen frequencies in HIV-1-related Kaposi's sarcoma. J Acquir Immune Defic Syndr 3 (1990) S51-S55
36. Gonzalez E., Dhanda R., Bamshad M., Mummidi S., Geevarghese R., Catano G., Anderson S.A., Walter E.A., Stephan K.T., Hammer M.F., et al. Global survey of genetic variation in CCR5, RANTES, and MIP-1alpha: impact on the epidemiology of the HIV-1 pandemic. Proc Natl Acad Sci USA 98 (2001) 5199-5204
37. Winkler C.A., Hendel H., Carrington M., Smith M.W., Nelson G.W., O'Brien S.J., Phair J., Vlahov D., Jacobson L.P., Rappoport J., et al. Dominant effects of CCR2-CCR5 haplotypes in HIV-1 disease progression. J Acquir Immune Defic Syndr 37 (2004) 1534-1538
38. Gonzalez E., Kulkarni H., Bolivar H., Mangano A., Sanchez R., Catano G., Nibbs R.J., Freedman B.I., Quinones M.P., Bamshad M.J., et al. The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility. Science 307 (2005) 1434-1440. This is a recent study that implicates CCL3L1 gene copy number (which reflects variable segmental gene duplication within and between populations) as a risk factor for HIV disease progression. It offers a new dimension to genetic disease association mapping.
39. Tang J., Shelton B., Makhatadze N.J., Zhang Y., Schaen M., Louie L.G., Goedert J.J., Seaberg E.C., Margolick J.B., Mellors J., and Kaslow R.A. Distribution of chemokine receptor CCR2 and CCR5 genotypes and their relative contribution to human immunodeficiency virus type 1 (HIV-1) seroconversion, early HIV-1 RNA concentration in plasma, and later disease progression. J Virol 76 (2002) 662-672
40. Cohen O.J., Vaccarezza M., Lam G.K., Baird B.F., Wildt K., Murphy P.M., Zimmerman P.A., Nutman T.B., Fox C.H., Hoover S., et al. Heterozygosity for a defective gene for CC chemokine receptor 5 is not the sole determinant for the immunologic and virologic phenotype of HIV-infected long-term nonprogressors. J Clin Invest 100 (1997) 1581-1589
41. Shepherd J.C., and Quinn T.C. Entry inhibitors: a primer on the class and on its most promising agents. Hopkins HIV Rep 16 (2004) 1-4
42. Fatkenheuer G., Pozniak A.L., Johnson M.A., Piettenberg A., Staszewski S., Hoepelman A.I., Saag M.S., Goebel F.D., Rockstroh J.K., Dezube B.J., et al. Efficacy of short-term monotherapy with maroviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med 11 (2005) 1170-1172. This is a high profile publication of this successful pilot study (n = 63, 10-day monotherapy treatment), which indicates the level of interest in this drug class. Note, however, that several CCR5 anatagonist drugs have been slow to progress through clinical trial phases because of significant drug reactions.
43. Glass W.G., McDermott D.H., Lim J.K., Lekhong S., Yu S.K., Frank W.A., Pape J., Cheshier R.C., and Murphy P.M. CCR5 deficiency increases risk of symptomatic West Nile virus infection. J Exp Med 203 (2006) 35-40. The authors report the fascinating discovery of increased disease severity and risk of death associated with CCR5Δ32 homozygosity in two US populations.
44. Glass W.G., Lim J.K., Cholera R., Pletnev A.G., Gao J.L., and Murphy P.M. Chemokine receptor CCR5 promotes leukocyte trafficking to the brain and survival in West Nile virus infection. J Exp Med 202 (2005) 1087-1098
45. Hayes E.B., and Gubler D.J. West Nile virus: epidemiology and clinical features of an emerging epidemic in the United States. Annu Rev Med 57 (2006) 181-194
46. Stein C.M., Nshuti L., Chiunda A.B., Boom W.H., Elston R.C., Mugerwa R.D., Iyengar S.K., and Whalen C.C. Evidence for a major gene influence on tumor necrosis factor-alpha expression in tuberculosis: path and segregation analysis. Hum Hered 60 (2005) 109-118. This study reports an interesting approach to genetic mapping associated with tuberculosis (TB) disease, which uses antigen-induced TNF-α as an 'endophenotype' for TB. This suggests a major gene model explaining one-third of disease outcome variability, after adjustment for effect of shared environment.
47. Smith I., Nathan C., Peavy H.H., and NHLBI working group. Progress and directions in genetics of tuberculosis: an NHLBI working group report. Am J Respir Crit Care Med 172 (2005) 1491-1496
48. + T cell immunity: HCV evolution, from chimpnzees to man. J Exp Med 201 (2005) 1709-1744
49. Mackinnon M.J., Mwangi T.W., Snow R.W., Marsh K., and Williams T.N. Heritability of malaria in Africa. PLoS Med 2 (2005) e340. This study finds that a surprisingly high proportion of malaria risk (∼25%) is attributable to genetic factors beyond the well known hemoglobinopathies.
50. Martin A.M., Freitas E.M., Witt C.S., and Christiansen F.T. The genomic organization and evolution of the natural killer immunoglobulin-like receptor (KIR) gene cluster. Immunogenetics 51 (2000) 268-280
51. Vilches C., and Parham P. KIR: diverse, rapidly evolving receptors of innate and adaptive immunity. Annu Rev Immunol 20 (2002) 217-251
52. Martin M.P., and Carrington M. Natural killer cells and HIV-1 disease. Curr Opin HIV AIDS 1 (2006) 226-231. A concise and well-written review of the current knowledge regarding NK cells and HIV-1 disease.
53. Flores-Villanueva P.O., Yunis E.J., Delgado J.C., Vittinghoff E., Buchbinder S., Leung J.Y., Uglialoro A.M., Clavijo O.P., Rosenberg E.S., Kalams S.A., et al. Control of HIV-1 viremia and protection from AIDS are associated with HLA-Bw4 homozygosity. Proc Natl Acad Sci USA 98 (2001) 5140-5145
54. Martin M.P., Gao X., Lee J.H., Nelson G.W., Detels R., Goedert J.J., Buchbinder S., Hoots K., Vlahov D., Trowsdale J., et al. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat Genet 31 (2002) 429-434
55. Gaudieri S., DeSantis D., McKinnon E., Moore C., Nolan D., Witt C.S., Mallal S.A., and Christiansen F.T. Killer immunoglobulin-like receptors and HLA act both independently and synergistically to modify HIV disease progression. Genes Immun 6 (2005) 683-690
56. Schwartz O., Marechal V., Le Gall S., Lemonnier F., and Heard J.M. Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 Nef protein. Nat Med 2 (1996) 338-342
57. Carrington M., and Martin M.P. The impact of variation at the KIR gene cluster on human disease. Curr Top Microbiol Immunol 298 (2006) 225-257
58. Zinkernagel R.M. Immunology taught by viruses. Science 271 (1996) 173-178
59. Kremeyer B., Hummel S., and Herrmann B. Frequency analysis of the delta32CCR5 HIV resistance allele in a medieval plague mass grave. Anthropol Anz 63 (2005) 13-22